Lp(a) testing and LDL-C levels among australian ASCVD patients in 2022: a cross-sectional study from the advara heartcare network (PREVAIL)

Back

ESC Professional Premium Access

Lp(a) testing and LDL-C levels among australian ASCVD patients in 2022: a cross-sectional study from the advara heartcare network (PREVAIL)

Session: Lp(a) and apoproteins as risk factors

Topic: Biomarkers

Speaker: Doctor R. SANTANI (Sydney, AU)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Ravi SANTANI

Sydney (Australia)

0 follower

7 more presentations in this session

Does the LPA genotype have a role in coronary artery disease risk beyond Lp(a) values?

Speaker: Doctor D. Sa (Funchal, PT)

Comparison of Lp(a) assessment in patients with atherosclerotic cardiovascular disease between office-based cardiologists and general practitioners

Speaker: Professor O. Weingaertner (Jena, DE)

Causal associations of insulin and Lp(a) levels: a Mendelian randomization study

Speaker: Associate Professor T. Osadnik (Zabrze, PL)

A retrospective analysis of patients with very HIGH level of LDL-C and the predictors of mortality (HIGH-LDL-PM Registry)

Speaker: Associate Professor U. Sinan (Istanbul, TR)

The prevalence, patients characteristics and risk factors of hyper-Lp(a)-emia in the Polish population. The first results from the PMMHRI-Lp(a) Registry

Speaker: Professor M. Banach (Lodz, PL)

Access the full session

Lp(a) and apoproteins as risk factors

Speakers: Doctor R. SANTANI, Doctor D. Sa, Professor O. Weingaertner, Associate Professor T. Osadnik, Associate Professor U. Sinan...

Access

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources